Filter
230
Text search:
Birth
defects
surveillance
Featured
18
82
Language
Document type
154
36
26
5
5
2
2
Countries / Regions
19
8
8
6
6
6
5
5
5
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
Authors & Publishers
Publication Years
Category
85
40
16
13
4
2
2
Toolboxes
28
25
11
10
9
7
7
6
6
5
5
4
3
3
3
3
2
1
Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers
This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva
...
The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early
...
Interim Guidance.
A number of medical problems have been reported in survivors, including mental health issues. Ebola virus may persist in some body fluids, including semen. Ebola survivors need comprehensive support for the medical and psychosocial challenges they face and also to minimize the ...
A number of medical problems have been reported in survivors, including mental health issues. Ebola virus may persist in some body fluids, including semen. Ebola survivors need comprehensive support for the medical and psychosocial challenges they face and also to minimize the ...
The objective of this document is to guide the preparation and implementation of national preparedness plans for the safety of substances of human origin during outbreaks of Zika virus infection, both in affected and non-affected areas.
BMC Medicine201614:112 DOI: 10.1186/s12916-016-0660-0
THELANCETID-D-16-00800 S1473-3099(16)30318-8
Health Systems in Transition. Vol. 5 No.3 2015
